Drug testing is not a routine part of prenatal care for most pregnant people in the United States. What is routine is verbal screening: your provider will likely ask questions about substance use at your first prenatal visit, and possibly again later in pregnancy. Whether an actual urine or blood test happens depends on your state, your hospital’s policies, specific clinical concerns, and importantly, your consent.
Screening vs. Actual Drug Testing
There’s an important distinction between screening and testing that often gets blurred. Screening means your provider asks you questions, either through a conversation or a short written questionnaire, about alcohol, tobacco, and drug use. This is considered the gold standard for identifying substance use during pregnancy, and medical guidelines recommend it be offered to every patient universally to reduce bias.
Toxicology testing is different. It involves collecting a biological sample, usually urine, and analyzing it for the presence of drugs or their byproducts. This is not recommended as a universal practice. The American College of Obstetricians and Gynecologists specifically cautions providers against using urine or hair testing as a screening tool, even for cannabis, because the results can’t accurately measure how much someone used or diagnose a substance use disorder. A positive urine test only tells you a substance was present at some point within its detection window, not how often or how recently it was used.
When Providers Order a Drug Test
Some hospitals and clinics do have policies that lead to drug testing during pregnancy or at delivery. The triggers vary widely, but common situations include: a newborn showing signs of withdrawal after birth, a placental abruption or other unexplained pregnancy complication, a mother arriving at the hospital with no prenatal care, or a positive answer on a verbal screening tool. Some facilities in certain states test more broadly than others.
This is where things get uneven. Research consistently shows that Black women and other minority patients are tested and reported to child protective services at disproportionately higher rates than white women, even when substance use rates are similar. ACOG has acknowledged this disparity directly and urges providers to be aware of it. Universal verbal screening, where every patient gets the same questions, is one way to reduce that bias compared to leaving testing decisions up to individual provider judgment.
Your Legal Right to Consent
The U.S. Supreme Court ruled that hospital workers cannot test pregnant women for illegal drugs without informed consent or a valid warrant when the purpose is connected to law enforcement. The case came from Charleston, South Carolina, where a public hospital had partnered with police to arrest women who tested positive for cocaine during prenatal visits. The court found, in a 6-to-3 decision, that testing a patient to gather evidence of criminal conduct is an unreasonable search under the Fourth Amendment if the patient hasn’t consented.
In practice, this means your provider should explain what they’re testing for and get your permission before running a toxicology screen. ACOG’s guidelines reinforce this: pregnant women should always be counseled about the risks and benefits of drug testing, and informed consent should be obtained before testing the mother or the newborn. That said, the specifics of how consent works can vary by state law and hospital policy. Some states have broader authority to test in certain clinical scenarios, so the protections aren’t perfectly uniform across the country.
What Happens at Delivery
The moment when drug testing is most likely to come up is at the hospital during or after delivery. Many hospitals have protocols for when to test newborns, and the baby can be tested separately from the mother. Newborn testing can be done on urine, blood, meconium (the baby’s first stool), hair, or umbilical cord tissue, each with a different detection window.
Urine testing gives the fastest results but drugs clear quickly, so a delay in collection can produce a false negative. Meconium begins forming in the second trimester, so a positive result typically reflects exposure over the last month or more before delivery. It’s generally more accurate than urine for identifying a pattern of use, but it can’t pinpoint exactly when exposure happened. Umbilical cord tissue testing is an alternative to meconium, though researchers still aren’t sure how far back into pregnancy it can detect exposure. First-time use right before delivery might not show up in meconium at all, since the drug may not have had time to deposit there.
State Laws and Child Protective Services
Federal law under the Child Abuse Prevention and Treatment Act (CAPTA) requires states to track the number of substance-affected newborns, though no identifiable patient information is shared with the federal government. Hospitals are also required to create a “Plan of Safe Care” for infants identified as affected by substance exposure, including those with fetal alcohol spectrum disorder or withdrawal symptoms. This plan is meant to address the infant’s needs and connect families with services.
Beyond the federal requirements, state laws diverge significantly. Twenty-four states and Washington, D.C. classify prenatal drug use as child abuse or neglect. In those states, a positive drug test during pregnancy or at delivery can trigger a report to child protective services. Other states take a treatment-oriented approach, prioritizing referrals to substance use programs rather than punitive action. The consequences of a positive test depend heavily on where you live, what substance is involved, and whether your state’s framework leans toward intervention or prosecution.
False Positives and Test Limitations
Initial drug screens use a method called immunoassay, which is fast but not perfectly specific. Certain prescription medications, over-the-counter drugs, and even some foods can trigger a false positive. If a screening test comes back positive, a second confirmatory test using a more precise method should be run before any conclusions are drawn. This is especially important given the legal and child welfare consequences that can follow a positive result during pregnancy.
Timing also matters. Urine tests only capture a narrow window of recent use, while meconium and cord tissue capture a broader but less precise timeline. No single test can tell a provider how much of a substance someone used, how often they used it, or whether a substance use disorder is present. That’s one of the core reasons ACOG recommends conversation-based screening over biological testing as a first-line approach: a thoughtful discussion with a provider gives more useful clinical information than a lab result alone.